Executive Summary
Seventy-one million people worldwide are infected with Hepatitis C (HCV), a blood-borne virus known as the "silent killer" due to the long period before people experience symptoms. With 1.75 million new infections and more than 400,000 deaths from cirrhosis and liver cancer every year, the epidemic is growing.
A revolutionary recently developed treatment cures 95 percent of people in weeks with a once-daily pill. Global commitment to eliminate HCV by 2030—and tools to do it—exist. But the current, haphazard “control” response, in which we wait until people become symptomatic to treat them, will solidify the virus infections and deaths as an epidemic that lasts centuries, much like tuberculosis.
Working closely with 12 governments toward curing more than nine million people and averting close to one million new infections, CHAI will put the world on track to end HCV forever and erase skepticism that this epidemic can be eliminated practically and affordably.
Charity, fund, non-governmental organization, religious institution, school, or other entity
Organizations may provide budget and employee data based on this proposal or the organization as a whole. For more information on this proposal or organization, please email us.
Accomplishments
The COVID-19 pandemic has caused numerous challenges to delivering HCV diagnostic, treatment, and prevention services. However, CHAI’s hepatitis program reached several key milestones over the past year.
In June 2020, CHAI published the first global Hepatitis C Market Report to provide market intelligence on HCV diagnostics and drugs in low- and middle-income countries (LMIC), calling attention to how LMIC can now diagnose, treat, and cure HCV patients for less than $100 per patient. The report highlights commodity ceiling prices and lowest prices secured and provides options for reducing in-country mark-ups. It can be used as a tool for governments, partners, and other community stakeholders to reduce commodity costs within their HCV elimination programs.
CHAI continues to support countries to secure investments for those infected with HCV. In Cambodia, Myanmar, and Vietnam, CHAI helped secure the Global Fund for HIV, TB, and Malaria (GFATM) investments for micro-elimination of HCV among people living with HIV.
